Scott Lisse, MD
Internal Medicine · Houston, TXNPI 1346245818
Payments from drug & device makers
Across 257 payments — averaging $16.62 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$779
- Amarin Pharma, Inc.$382
- Astellas Pharma US Inc$328
- Merck$220
- AbbVie$202
- Abbott$199
- plus $2K from 29 others
What the payments were for
- Speaking & faculty fees$451%
- Food & beverage$4,21299%
- Education$140%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk | 44 | $779 |
| Amarin Pharma, Inc. | 27 | $382 |
| Astellas Pharma US Inc | 16 | $328 |
| Merck | 19 | $220 |
| AbbVie(2 entities) | 14 | $202 |
| Abbott | 7 | $199 |
| Johnson & Johnson | 14 | $196 |
| Lilly USA, LLC | 17 | $180 |
| Inspire Medical Systems, Inc. | 6 | $157 |
| Sanofi-aventis U.S. LLC | 8 | $146 |
| Gilead | 10 | $138 |
| GSK | 8 | $137 |
| Boehringer Ingelheim | 9 | $134 |
| Vanda Pharmaceuticals Inc. | 6 | $132 |
| AstraZeneca | 9 | $122 |
| Pfizer | 6 | $108 |
| Dexcom, Inc. | 4 | $87 |
| Takeda Pharmaceuticals U.S.A., Inc. | 4 | $83 |
| Teva Pharmaceuticals USA, Inc. | 3 | $60 |
| Medtronic | 1 | $56 |
| Amgen | 4 | $54 |
| Sanofi Pasteur Inc. | 2 | $43 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 3 | $42 |
| Genentech USA, Inc. | 2 | $31 |
| Shire North American Group Inc | 2 | $30 |
| EMD Serono, Inc. | 1 | $28 |
| Abiomed | 1 | $28 |
| Ironshore Pharmaceuticals Inc. | 2 | $27 |
| Titan Spine, LLC | 1 | $24 |
| Idorsia Pharmaceuticals US Inc | 1 | $24 |
| Amneal Pharmaceuticals LLC | 2 | $23 |
| Novartis | 1 | $21 |
| Metuchen Pharmaceuticals | 1 | $20 |
| Assertio Therapeutics, Inc. | 1 | $19 |
| Jazz Pharmaceuticals Inc. | 1 | $11 |
How this compares
$4,271 in reported general payments places this provider in the 85th percentile of 7,675 internal medicine providers in Texas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| MounjaroTirzepatide | 185 | $321,789 |
| JardianceEmpagliflozin | 68 | $90,806 |
| OzempicSemaglutide | 49 | $77,744 |
| XareltoRivaroxaban | 25 | $36,180 |
| EliquisApixaban | 27 | $29,126 |
| JanuviaSitagliptin Phosphate | 12 | $18,336 |
| Synjardy XrEmpagliflozin/Metformin Hcl | 14 | $17,577 |
| ShingrixVaricella-Zoster Ge/As01b/Pf | 67 | $14,889 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 13 | $14,298 |
| Tresiba Flextouch U-100Insulin Degludec | 11 | $12,101 |
| FarxigaDapagliflozin Propanediol | 11 | $10,258 |
| Rosuvastatin Calcium | 716 | $10,218 |
| SynthroidLevothyroxine Sodium | 99 | $9,010 |
| VascepaIcosapent Ethyl | 12 | $8,379 |
| LevemirInsulin Detemir | 14 | $5,082 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCMounjaro | $180 | $321,789185 claims |
| Boehringer IngelheimJardiance, Synjardy Xr | $134 | $108,38382 claims |
| Novo NordiskOzempic, Levemir | $779 | $82,82563 claims |
| Johnson & JohnsonXarelto | $196 | $36,18025 claims |
| GSKShingrix, Anoro Ellipta | $137 | $29,18780 claims |
| PfizerEliquis | $108 | $29,12627 claims |
| MerckJanuvia | $220 | $18,33612 claims |
| AstraZenecaFarxiga | $122 | $10,25811 claims |
| AbbVieSynthroid | $202 | $9,01099 claims |
| Amneal Pharmaceuticals LLCLevothyroxine Sodium | $23 | $3,282283 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 7,675 internal medicine providers in Texas.
Other internal medicine in Houston
- Jan BurgerHouston$47.3M
- Nitin JainHouston$33.2M
- Aung NaingHouston$30.6M
- Preetesh JainHouston$19.5M
- Paolo StratiHouston$19.2M
- Nicholas ShortHouston$17.6M
- Isabella GlitzaHouston$14.8M
- Murtaza MussajiHouston$13.1M
- Hussein TawbiHouston$12.6M
- Hans LeeHouston$11.7M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.